1. Home
  2. XXII vs PCSA Comparison

XXII vs PCSA Comparison

Compare XXII & PCSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 22nd Century Group Inc.

XXII

22nd Century Group Inc.

HOLD

Current Price

$0.76

Market Cap

6.1M

Sector

Health Care

ML Signal

HOLD

Logo Processa Pharmaceuticals Inc.

PCSA

Processa Pharmaceuticals Inc.

HOLD

Current Price

$2.88

Market Cap

8.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
XXII
PCSA
Founded
1998
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.1M
8.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
XXII
PCSA
Price
$0.76
$2.88
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$25.00
AVG Volume (30 Days)
166.9K
2.3M
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$20,346,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$79.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
16.98
N/A
52 Week Low
$0.75
$2.74
52 Week High
$287.27
$27.00

Technical Indicators

Market Signals
Indicator
XXII
PCSA
Relative Strength Index (RSI) 31.02 56.69
Support Level $0.90 $3.32
Resistance Level $0.88 $4.04
Average True Range (ATR) 0.07 0.80
MACD -0.01 0.04
Stochastic Oscillator 2.25 31.59

Price Performance

Historical Comparison
XXII
PCSA

About XXII 22nd Century Group Inc.

22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.

About PCSA Processa Pharmaceuticals Inc.

Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).

Share on Social Networks: